Expansion and intensification of humoral autoimmune response in the transition from preclinical to full‐blown primary biliary cholangitis
Alessandra Dellavance, Maria L.G. Ferraz, Eduardo L.R. Cançado, Luís E.C. Andrade – 16 May 2017
Immortal time bias or sorafenib effect in elderly patients with HCC?
Hanna K. Sanoff, YunKyung Chang, Jennifer L. Lund, Bert H. O'Neil, Stacie B. Dusetzina – 16 May 2017
Reply
Christophe Corpechot, Géraldine Dahlqvist, Olivier Chazouillères, Catherine Johanet – 16 May 2017
Regulatory T cell signatures in liver transplant recipients successfully weaned from immunosuppression: Getting from here to there
Matthew H. Levine, Tatiana Akimova, Douglas R. Murken, Wayne W. Hancock – 15 May 2017
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
Varun Saxena, Vandana Khungar, Elizabeth C. Verna, Josh Levitsky, Robert S. Brown, Mohamed A. Hassan, Mark S. Sulkowski, Jacqueline G. O'Leary, Farrukh Koraishy, Joseph S. Galati, Alexander A. Kuo, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael W. Fried, Norah Terrault, K. Rajender Reddy – 15 May 2017 – Data outside of clinical trials with direct‐acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.
The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance
Quan‐Yu Zhang, Ling‐Ping Zhao, Xiao‐Xiang Tian, Cheng‐Hui Yan, Yang Li, Yan‐Xia Liu, Pi‐Xiao Wang, Xiao‐Jing Zhang, Ya‐Ling Han – 15 May 2017 – Cellular repressor of E1A‐stimulated genes (CREG), a novel cellular glycoprotein, has been identified as a suppressor of various cardiovascular diseases because of its capacity to reduce hyperplasia, maintain vascular homeostasis, and promote endothelial restoration. However, the effects and mechanism of CREG in metabolic disorder and hepatic steatosis remain unknown.
CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice
Michael Zimmer, Pradeep Bista, Ericka L. Benson, Diana Y. Lee, Feng Liu, Dominic Picarella, Rick B. Vega, Chi B. Vu, Maisy Yeager, Min Ding, Guosheng Liang, Jay D. Horton, Robert Kleemann, Teake Kooistra, Martine C. Morrison, Peter Y. Wielinga, Jill C. Milne, Michael R. Jirousek, Andrew J. Nichols – 12 May 2017 – CAT‐2003 is a novel conjugate of eicosapentaenoic acid (EPA) and niacin designed to be hydrolyzed by fatty acid amide hydrolase to release EPA inside cells at the endoplasmic reticulum.
Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection
Romain Désert, Florian Rohart, Frédéric Canal, Marie Sicard, Mireille Desille, Stéphanie Renaud, Bruno Turlin, Pascale Bellaud, Christine Perret, Bruno Clément, Kim‐Anh Lê Cao, Orlando Musso – 12 May 2017 – Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates.
Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen
Edward J. Gane, Mitchell L. Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine A.M. Stedman, Mitchell N. Davis, Federico Hinestrosa, Hadas Dvory‐Sobol, K.C. Huang, Anu Osinusi, John McNally, Diana M. Brainard, John G. McHutchison, Alex J. Thompson, Mark S. Sulkowski, GS‐US‐342‐1553 Investigators – 12 May 2017 – The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct‐acting antiviral–based therapies remains unclear.